LIVIVO - Search results -

Search results

Result 1 - 10 of total 53

Search options

Article ; Online: A ban on BAM: an update on inhibitors of the β-barrel assembly machinery.

Steenhuis, Maurice / van Ulsen, Peter / Martin, Nathaniel I / Luirink, Joen

2021 Volume 368, Issue 11

Abstract: Gram-negative pathogens are a rapidly increasing threat to human health worldwide due to high rates of antibiotic resistance and the lack of development of novel antibiotics. The protective cell envelope of gram-negative bacteria is a major permeability ... ...

Abstract	Gram-negative pathogens are a rapidly increasing threat to human health worldwide due to high rates of antibiotic resistance and the lack of development of novel antibiotics. The protective cell envelope of gram-negative bacteria is a major permeability barrier that contributes to the problem by restricting the uptake of antibiotics. On the other hand, its unique architecture also makes it a suitable target for antibiotic interference. In particular, essential multiprotein machines that are required for biogenesis of the outer membrane have attracted attention in antibacterial design strategies. Recently, significant progress has been made in the development of inhibitors of the β-barrel assembly machine (BAM) complex. Here, we summarize the current state of drug development efforts targeting the BAM complex in pursuit of new antibiotics.
MeSH term(s)	Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/pharmacology ; Bacterial Outer Membrane/drug effects ; Bacterial Outer Membrane/metabolism ; Bacterial Outer Membrane Proteins/antagonists & inhibitors ; Bacterial Outer Membrane Proteins/genetics ; Bacterial Outer Membrane Proteins/metabolism ; Drug Resistance, Bacterial/genetics ; Gram-Negative Bacteria/drug effects ; Gram-Negative Bacteria/pathogenicity ; Humans ; Mutation ; Virulence/drug effects
Chemical Substances	Anti-Bacterial Agents ; Bacterial Outer Membrane Proteins
Language	English
Publishing date	2021-08-26
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	752343-9
ISSN	1574-6968 ; 0378-1097
ISSN (online)	1574-6968
ISSN	0378-1097
DOI	10.1093/femsle/fnab059
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1372: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Quality assessment and harmonization of laboratories across Europe for multiple SARS-CoV-2 serology assays.

Steenhuis, Maurice / Wouters, Elise / Schrezenmeier, Hubert / Rispens, Theo / Tiberghien, Pierre / Harvala, Heli / Feys, Hendrik B / van der Schoot, C Ellen

Vox sanguinis

2023 Volume 118, Issue 8, Page(s) 666–673

Abstract: Background and objectives: There is a need for conversion of SARS-CoV-2 serology data from different laboratories to a harmonized international unit. We aimed to compare the performance of multiple SARS-CoV-2 antibody serology assays among 25 ... ...

Abstract	Background and objectives: There is a need for conversion of SARS-CoV-2 serology data from different laboratories to a harmonized international unit. We aimed to compare the performance of multiple SARS-CoV-2 antibody serology assays among 25 laboratories across 12 European countries. Materials and methods: To investigate this we have distributed to all participating laboratories a panel of 15 SARS-CoV-2 plasma samples and a single batch of pooled plasma calibrated to the WHO IS 20/136 standard. Results: All assays showed excellent discrimination between SARS-CoV-2 seronegative plasma samples and pre-vaccinated seropositive plasma samples but differed substantially in raw antibody titres. Titres could be harmonized to binding antibody units per millilitre by calibration in relation to a reference reagent. Conclusion: The standardization of antibody quantification is of paramount importance to allow interpretation and comparison of serology data reported in clinical trials in order to identify donor cohorts from whom the most effective convalescent plasma can be collected.
MeSH term(s)	Humans ; SARS-CoV-2 ; COVID-19/diagnosis ; Laboratories ; COVID-19 Serotherapy ; Europe ; Antibodies, Viral ; COVID-19 Testing
Chemical Substances	Antibodies, Viral
Language	English
Publishing date	2023-07-04
Publishing country	England
Document type	Journal Article
ZDB-ID	80313-3
ISSN	1423-0410 ; 0042-9007
ISSN (online)	1423-0410
ISSN	0042-9007
DOI	10.1111/vox.13480
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 74: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Fingerprick blood samples to measure serum natalizumab concentrations.

Toorop, Alyssa A / Steenhuis, Maurice / Loeff, Floris C / Weijers, Suzanne S / Killestein, Joep / Rispens, Theo / Kempen, Zoé LE van

Multiple sclerosis (Houndmills, Basingstoke, England)

2022 Volume 29, Issue 3, Page(s) 457–460

Abstract: Background: Natalizumab via subcutaneous administration was recently approved for patients with multiple sclerosis.: Objective: In light of personalized extended dosing, in which treatment intervals are prolonged to a concentration cut-off, it would ... ...

Abstract	Background: Natalizumab via subcutaneous administration was recently approved for patients with multiple sclerosis. Objective: In light of personalized extended dosing, in which treatment intervals are prolonged to a concentration cut-off, it would be preferable to measure natalizumab drug concentrations in capillary blood. Methods: In this cross-sectional study in patients treated with intravenous (IV) natalizumab, capillary blood samples by fingerprick and venous blood samples were collected in 30 participants prior to IV administration of natalizumab. Results: Natalizumab concentrations were similar with a mean bias of -0.36 μg/mL (95% CI: 1.3 to -2 μg/mL). Conclusions: This study shows that physicians can monitor natalizumab drug concentrations by a fingerprick, which could be used for personalized extended dosing.
MeSH term(s)	Humans ; Natalizumab/therapeutic use ; Cross-Sectional Studies ; Multiple Sclerosis/drug therapy ; Risk Factors ; Administration, Intravenous ; Immunologic Factors/adverse effects ; Multiple Sclerosis, Relapsing-Remitting/drug therapy
Chemical Substances	Natalizumab ; Immunologic Factors
Language	English
Publishing date	2022-11-30
Publishing country	England
Document type	Journal Article
ZDB-ID	1290669-4
ISSN	1477-0970 ; 1352-4585
ISSN (online)	1477-0970
ISSN	1352-4585
DOI	10.1177/13524585221136448
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4428: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatology.

Besten, Yaëlle R / Boekel, Laura / Steenhuis, Maurice / Hooijberg, Femke / Atiqi, Sadaf / Leeuw, Maureen / Vogelzang, Erik H / Keijser, Jim / Keijzer, Sofie / Loeff, Floris C / Gerritsen, Martijn / Tas, Sander W / Nurmohamed, Michael T / Rispens, Theo / Wolbink, Gertjan

RMD open

2024 Volume 10, Issue 2

Abstract: Background: During the COVID-19 pandemic, we developed a digital research platform to longitudinally investigate COVID-19-related outcomes in patients with rheumatic diseases and healthy controls. We used home finger-prick testing in order to collect ... ...

Abstract	Background: During the COVID-19 pandemic, we developed a digital research platform to longitudinally investigate COVID-19-related outcomes in patients with rheumatic diseases and healthy controls. We used home finger-prick testing in order to collect serum samples remotely and increase the overall efficiency of the platform. The aim of the present study was to evaluate the success rate of the finger prick and patients' perspective towards the finger prick. Methods: Serum samples were collected up to five times during follow-up, either via a venepuncture at the research institute or a finger prick from participants' home. Participants were asked to complete a digital evaluation questionnaire of the finger prick after their attempts. Results: A total of 2135 patients and 899 controls performed at least one finger prick and were included in this study. The first finger prick was successfully done by 92% (95% CI: 90% to 93%) of patients, 94% (95% CI: 92% to 95%) of controls, 93% (95% CI: 92% to 94%) of all participants aged ≤70 years and 89% (95% CI: 86% to 92%) of all participants aged >70 years. Sex did not impact these success rates. Repeated failure occurred in 11/439 (0.8%) patients and 4/712 (0.6%) controls. Both patients and controls were less willing to perform a finger prick for individual healthcare compared with scientific research. Conclusion: The vast majority of participants, among which elderly and patients with rheumatic diseases, were able to successfully draw the required amount of blood for serological analyses. This shows that finger-prick testing is suitable for a high-throughput implementation to monitor patients remotely.
MeSH term(s)	Aged ; Humans ; Rheumatology ; Pandemics ; Feasibility Studies ; Blood Specimen Collection ; COVID-19/diagnosis ; COVID-19/epidemiology ; Rheumatic Diseases/diagnosis
Language	English
Publishing date	2024-04-19
Publishing country	England
Document type	Journal Article
ZDB-ID	2812592-7
ISSN	2056-5933 ; 2056-5933
ISSN (online)	2056-5933
ISSN	2056-5933
DOI	10.1136/rmdopen-2023-003933
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Stress-Based High-Throughput Screening Assays to Identify Inhibitors of Cell Envelope Biogenesis.

Steenhuis, Maurice / Ten Hagen-Jongman, Corinne M / van Ulsen, Peter / Luirink, Joen

Antibiotics (Basel, Switzerland)

2020 Volume 9, Issue 11

Abstract: The structural integrity of the Gram-negative cell envelope is guarded by several stress responses, such as the ... ...

Abstract	The structural integrity of the Gram-negative cell envelope is guarded by several stress responses, such as the σ
Language	English
Publishing date	2020-11-13
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics9110808
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Dual Action of Eeyarestatin 24 on Sec-Dependent Protein Secretion and Bacterial DNA.

Schäfer, Ann-Britt / Steenhuis, Maurice / Jim, Kin Ki / Neef, Jolanda / O'Keefe, Sarah / Whitehead, Roger C / Swanton, Eileithyia / Wang, Biwen / Halbedel, Sven / High, Stephen / van Dijl, Jan Maarten / Luirink, Joen / Wenzel, Michaela

ACS infectious diseases

2023 Volume 9, Issue 2, Page(s) 253–269

Abstract: Eeyarestatin 24 (ES24) is a promising new antibiotic with broad-spectrum activity. It shares structural similarity with nitrofurantoin (NFT), yet appears to have a distinct and novel mechanism: ES24 was found to inhibit SecYEG-mediated protein transport ... ...

Abstract	Eeyarestatin 24 (ES24) is a promising new antibiotic with broad-spectrum activity. It shares structural similarity with nitrofurantoin (NFT), yet appears to have a distinct and novel mechanism: ES24 was found to inhibit SecYEG-mediated protein transport and membrane insertion in Gram-negative bacteria. However, possible additional targets have not yet been explored. Moreover, its activity was notably better against Gram-positive bacteria, for which its mechanism of action had not yet been investigated. We have used transcriptomic stress response profiling, phenotypic assays, and protein secretion analyses to investigate the mode of action of ES24 in comparison with NFT using the Gram-positive model bacterium
MeSH term(s)	Animals ; Escherichia coli/genetics ; Escherichia coli/metabolism ; DNA, Bacterial ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/metabolism ; Zebrafish ; Gram-Negative Bacteria/metabolism ; Gram-Positive Bacteria ; Protein Transport
Chemical Substances	DNA, Bacterial ; Anti-Bacterial Agents
Language	English
Publishing date	2023-01-13
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2373-8227
ISSN (online)	2373-8227
DOI	10.1021/acsinfecdis.2c00404
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease.

Otten, Antonius T / van der Meulen, Hedwig H / Steenhuis, Maurice / Loeff, Floris C / Touw, Daan J / Kosterink, Jos G W / Frijlink, Henderik W / Rispens, Theo / Dijkstra, Gerard / Visschedijk, Marijn C / Bourgonje, Arno R

Inflammatory bowel diseases

2023 Volume 30, Issue 3, Page(s) 325–335

Abstract: Background: Therapeutic drug monitoring provides important guidance for treatment of patients with inflammatory bowel disease (IBD) and could help to early identify treatment failure. This study aimed to validate a finger prick-based capillary blood ... ...

Abstract	Background: Therapeutic drug monitoring provides important guidance for treatment of patients with inflammatory bowel disease (IBD) and could help to early identify treatment failure. This study aimed to validate a finger prick-based capillary blood sampling technique to measure biological trough levels and C-reactive protein (CRP) and evaluate patient performance and -support. Methods: In this prospective cohort study, patients with IBD receiving infliximab (IFX) or vedolizumab (VEDO) therapy performed finger prick-based capillary blood sampling at home. Additionally, blood was collected through routinely performed in-hospital venepuncture prior to biological infusion. IFX, VEDO, and CRP concentrations were measured by enzyme-linked immunosorbent assay. The concordance between methods was statistically evaluated and a survey was conducted to assess practicality and patient support. Results: In total, 81 patients (46 IFX, 35 VEDO) were enrolled. Mean differences between both methods were 0.42 (95% confidence interval, -1.74 to 2.58) μg/mL for IFX and 0.72 (95% confidence interval, -5.50 to 6.94) μg/mL for VEDO. Passing-Bablok regressions demonstrated no evidence for systematic or proportional biases. Venous and capillary IFX (ρ = 0.96, P < .001) and VEDO (ρ = 0.97, P < .001) levels strongly correlated and showed high intermethod agreement (Cohen's kappa: IFX = 0.82; VEDO = 0.94). Similarly, venous and capillary CRP levels were strongly correlated (ρ = 0.99, P < .001). Most patients (>95%) were able to successfully perform the self-sampling at home without prior instructions. Conclusions: This study clinically validated a finger prick-based capillary blood self-sampling technique allowing concomitant home monitoring of biological levels and CRP for patients with IBD, who reported substantial support, tolerability, and practicality.
MeSH term(s)	Humans ; Antibodies, Monoclonal, Humanized ; C-Reactive Protein ; Inflammatory Bowel Diseases/drug therapy ; Infliximab/pharmacokinetics ; Infliximab/therapeutic use ; Prospective Studies
Chemical Substances	Antibodies, Monoclonal, Humanized ; C-Reactive Protein (9007-41-4) ; Infliximab (B72HH48FLU) ; vedolizumab (9RV78Q2002)
Language	English
Publishing date	2023-05-17
Publishing country	England
Document type	Journal Article
ZDB-ID	1340971-2
ISSN	1536-4844 ; 1078-0998
ISSN (online)	1536-4844
ISSN	1078-0998
DOI	10.1093/ibd/izad103
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4530: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort.

van Kempen, Zoé L E / Strijbis, Eva M M / Al, Marissa M C T / Steenhuis, Maurice / Uitdehaag, Bernard M J / Rispens, Theo / Killestein, Joep

JAMA neurology

2021 Volume 78, Issue 7, Page(s) 880–882

MeSH term(s)	Adult ; Aged ; Antibodies, Viral/analysis ; COVID-19/complications ; COVID-19/epidemiology ; COVID-19/immunology ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Multiple Sclerosis/complications ; Multiple Sclerosis/epidemiology ; Netherlands/epidemiology ; Prospective Studies
Chemical Substances	Antibodies, Viral
Language	English
Publishing date	2021-04-30
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2702023-X
ISSN	2168-6157 ; 2168-6149
ISSN (online)	2168-6157
ISSN	2168-6149
DOI	10.1001/jamaneurol.2021.1364
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.191: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients.

Messchendorp, A Lianne / Sanders, Jan-Stephan F / Abrahams, Alferso C / Bemelman, Frederike J / Bouwmans, Pim / van den Dorpel, René M A / Hilbrands, Luuk B / Imhof, Céline / Reinders, Marlies E J / Rispens, Theo / Steenhuis, Maurice / Ten Dam, Marc A G J / Vart, Priya / de Vries, Aiko P J / Hemmelder, Marc H / Gansevoort, Ron T / Recovac Investigators

Viruses

2024 Volume 16, Issue 1

Abstract: Kidney transplant recipients (KTRs) elicit an impaired immune response after COVID-19 vaccination; however, the exact clinical impact remains unclear. We therefore analyse the relationship between antibody levels after vaccination and the risk of COVID- ... ...

Abstract	Kidney transplant recipients (KTRs) elicit an impaired immune response after COVID-19 vaccination; however, the exact clinical impact remains unclear. We therefore analyse the relationship between antibody levels after vaccination and the risk of COVID-19 in a large cohort of KTRs. All KTRs living in the Netherlands were invited to send a blood sample 28 days after their second COVID-19 vaccination for measurement of their IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein (anti-RBD IgG). Information on COVID-19 was collected from the moment the blood sample was obtained until 6 months thereafter. Multivariable Cox and logistic regression analyses were performed to analyse which factors affected the occurrence and severity (i.e., hospitalization and/or death) of COVID-19. In total, 12,159 KTRs were approached, of whom 2885 were included in the analyses. Among those, 1578 (54.7%) became seropositive (i.e., anti-RBD IgG level >50 BAU/mL). Seropositivity was associated with a lower risk for COVID-19, also after adjusting for multiple confounders, including socio-economic status and adherence to COVID-19 restrictions (HR 0.37 (0.19-0.47),
MeSH term(s)	Humans ; Incidence ; COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19 Vaccines ; Kidney Transplantation ; SARS-CoV-2 ; Immunoglobulin G ; Spike Glycoprotein, Coronavirus
Chemical Substances	spike protein, SARS-CoV-2 ; COVID-19 Vaccines ; Immunoglobulin G ; Spike Glycoprotein, Coronavirus
Language	English
Publishing date	2024-01-12
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v16010114
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection.

Keijzer, Sofie / Oskam, Nienke / Ooijevaar-de Heer, Pleuni / Steenhuis, Maurice / Keijser, Jim B D / Wieske, Luuk / van Dam, Koos P J / Stalman, Eileen W / Kummer, Laura Y L / Boekel, Laura / Kuijpers, Taco W / Ten Brinke, Anja / van Ham, S Marieke / Eftimov, Filip / Tas, Sander W / Wolbink, Gerrit J / Rispens, Theo

Frontiers in immunology

2024 Volume 15, Page(s) 1314507

Abstract: Background: Rheumatoid factors (RFs) are autoantibodies that target the Fc region of IgG, and are found in patients with rheumatic diseases as well as in the healthy population. Many studies suggest that an immune trigger may (transiently) elicit RF ... ...

Abstract	Background: Rheumatoid factors (RFs) are autoantibodies that target the Fc region of IgG, and are found in patients with rheumatic diseases as well as in the healthy population. Many studies suggest that an immune trigger may (transiently) elicit RF responses. However, discrepancies between different studies make it difficult to determine if and to which degree RF reactivity can be triggered by vaccination or infection. Objective: We quantitatively explored longitudinal RF responses after SARS-CoV-2 vaccination and infection in a well-defined, large cohort using a dual ELISA method that differentiates between true RF reactivity and background IgM reactivity. In addition, we reviewed existing literature on RF responses after vaccination and infection. Methods: 151 healthy participants and 30 RA patients were included to measure IgM-RF reactivity before and after SARS-CoV-2 vaccinations by ELISA. Additionally, IgM-RF responses after a SARS-CoV-2 breakthrough infection were studied in 51 healthy participants. Results: Published prevalence studies in subjects after infection report up to 85% IgM-RF seropositivity. However, seroconversion studies (both infection and vaccination) report much lower incidences of 2-33%, with a trend of lower percentages observed in larger studies. In the current study, SARS-CoV-2 vaccination triggered low-level IgM-RF responses in 5.5% (8/151) of cases, of which 1.5% (2/151) with a level above 10 AU/mL. Breakthrough infection was accompanied by development of an IgM-RF response in 2% (1/51) of cases. Conclusion: Our study indicates that
MeSH term(s)	Humans ; Rheumatoid Factor ; Arthritis, Rheumatoid ; Breakthrough Infections ; COVID-19 Vaccines ; SARS-CoV-2 ; COVID-19/prevention & control ; Autoantibodies ; Immunoglobulin M ; Vaccination
Chemical Substances	Rheumatoid Factor (9009-79-4) ; COVID-19 Vaccines ; Autoantibodies ; Immunoglobulin M
Language	English
Publishing date	2024-02-29
Publishing country	Switzerland
Document type	Review ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2024.1314507
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito